

Connecticut Pub. Act 23-171 Disclosure

PREVYMIS® (letermovir)

Merck Sharp & Dohme LLC (“Merck”) provides the following information to Connecticut prescribers, in accordance with Conn. Pub. Act 23-171.

The pricing information below reflects Merck’s Wholesale Acquisition Costs (“WAC”) for the Merck product(s) listed below. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the price(s) listed, depending, for example, on how the customer purchases the product(s), the availability of discounts, the wholesaler/distributor, and/or other charges.

WAC for Merck Product

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
PREVYMIS® (letermovir) 240 mg Tablets	00006-3075-02	Unit-of-use carton of 28. Package consists of one (1) 7-count aluminum blister card individually packaged inside a Child Resistant (CR) paperboard folding blister pack. Four (4) blister packs will be packaged into a folding carton.	\$7,316.96
PREVYMIS® (letermovir) 240 mg Tablets	00006-3075-04	Unit-of-use carton of 14. Package consists of two (2) 7-count perforated aluminum blister cards packaged inside a folding carton.	\$3,658.48
PREVYMIS® (letermovir) 480 mg Tablets	00006-3076-02	Unit-of-use carton of 28. Package consists of one (1) 7-count aluminum blister card individually packaged inside a Child Resistant (CR) paperboard folding blister pack. Four (4) blister packs will be packaged into a folding carton.	\$7,316.96
PREVYMIS® (letermovir) 480 mg Tablets	00006-3076-04	Unit-of-use carton of 14. Package consists of two (2) 7-count perforated aluminum blister cards packaged inside a folding carton.	\$3,658.48
PREVYMIS® (letermovir) 240 mg injection, for intravenous use	00006-5003-01	Single 30-mL vial	\$361.44
PREVYMIS® (letermovir) 480 mg injection, for intravenous use	00006-5004-01	Single 30-mL vial	\$361.44

Additional Information

In accordance with Conn. Pub. Act No. 23-171, Sec. 5(2), for information on efficacy by racial and ethnic group for the product(s) listed above, if available, please refer to the United States Food and Drug Administration (“FDA”) approved Prescribing Information and/or the FDA’s Drug Trials Snapshots database (available online at <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots>).

Copies of the Prescribing Information are available through the Merck representative who has provided you with this disclosure form as well as online at Merckconnect.com or Merckvaccines.com (for vaccines only).

The trademarks or service marks herein are owned by, licensed to, promoted by, or distributed by Merck & Co., Inc., its subsidiaries or its affiliates.

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-CYT-01721 01/24